In June 2018, the 64th annual meeting of the American Society of Artificial Organs was held in Chicago, USA. Dr. Chen Chen, CEO of the company, and Dr. Lin Feng, CTO of the company, were invited to attend the conference and delivered a plenary speech.
At the conference, Dr. Chen delivered a plenary speech on the theme of "Case Report: CH-VAD® Stage 1 Clinical Study in China". Dr. Chen introduced the technical characteristics and the latest research progress of CH-VAD®. CH-VAD® is an ultra-compact, fully magnetically levitated, implantable blood pump with centrifugal flow for the treatment of patients with advanced heart failure (HF). Over the past 10 years, great efforts have been made in flow path optimization, magnetic levitation design and system integration to reduce adverse events (stroke, infection, bleeding, etc.) thus to improve the safety and functionality of the device. From June to October in 2017, CH-VAD®s were implanted to three patients who "are sure to have no other means to save their lives" under the Humanitarian Device Exemption (HDE) approval application. All three patients’ conditions were significantly improved after operations. One patient decided to carry it for Long- Term support, another patient’s VAD was explanted electively for heart transplant, and another one was completely recovered from heart failure and the device was explanted. These achievements set a historical precedent for the application of artificial heart in China. Dr. Chen's report attracted high attention and heated discussion of the participants, who were excited about the success of VAD development in China.
This event was sponsored by the American Society for Artificial Organs (ASAIO). With a history of more than fifty years, ASAIO is committed to promoting the development of innovative medical devices by providing a forum for the development of innovative medical device technologies at the intersection of science, engineering, and medicine; and providing a platform for the collaboration and exchange for experts and scholars in various fields around the world. By participating in this international academic conference, CH Biomedical had a broad discussion with international colleagues in the industry, and showed the latest achievements in research and development, which further enhanced its influence in the field of miniaturized fully magnetically levitated VAD.
On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.
